biocryst pharmaceuticals extends cfo consulting agreement

BioCryst Pharmaceuticals , Inc. (NASDAQ:BCRX), based in Durham, North Carolina, announced the extension of its consulting agreement with former Chief Financial Officer Anthony Doyle. This information was disclosed in a recent SEC filing. The company, with a market capitalization of $2.34 billion, has shown impressive momentum with a 66% return over the past year and revenue of $503 million in the last twelve months.

The original consulting agreement, effective since April 9, 2025, allows Doyle to provide transition services to the company for a fee of $450 per hour. As of May 31, 2025, the term of this agreement has been extended through December 31, 2025. After this date, the agreement will continue on a month-to-month basis, subject to termination by either party with a thirty days’ written notice. According to InvestingPro, the company maintains a healthy financial position with a current ratio of 2.93, indicating strong liquidity to meet short-term obligations.

BioCryst Pharmaceuticals is listed on the Nasdaq Global Select Market under the ticker symbol BCRX. The company operates within the biological products industry, excluding diagnostic substances. This extension aims to ensure continuity during the transition of the Chief Financial Officer role.

The company’s decision to extend the agreement reflects its ongoing efforts to maintain stability in its financial operations. All other terms of the agreement remain unchanged. This report is based on a press release statement.

In other recent news, BioCryst Pharmaceuticals has reported a significant increase in its Q1 2025 revenue, reaching $145.5 million, surpassing the forecasted $127.9 million. This increase was largely driven by the strong sales of their leading product, Orladeyo, which accounted for $134 million, marking a 51% year-over-year growth. The company has subsequently raised its annual revenue guidance for Orladeyo to a range of $580-600 million. Jefferies has maintained a Buy rating on BioCryst, increasing the price target from $12.00 to $14.00 due to the robust sales performance and promising pipeline updates.

Additionally, BioCryst presented new data on Orladeyo at recent conferences, highlighting its effectiveness in reducing hereditary angioedema (HAE) attack rates in both adolescents and patients with severe HAE. Real-world evidence showed a substantial decrease in monthly attack rates among patients, reinforcing the drug’s efficacy. The company is also advancing its pipeline, with upcoming data expected on treatments for Netherton syndrome and diabetic macular edema later this year.

BioCryst continues to emphasize its commitment to improving the lives of those with HAE and other rare diseases through its innovative drug design approach. These developments reflect the company’s strong market position and strategic initiatives, setting a positive tone for its future trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.